NO20063843L - Polymorfe formar av en GABA-A-agonist - Google Patents

Polymorfe formar av en GABA-A-agonist

Info

Publication number
NO20063843L
NO20063843L NO20063843A NO20063843A NO20063843L NO 20063843 L NO20063843 L NO 20063843L NO 20063843 A NO20063843 A NO 20063843A NO 20063843 A NO20063843 A NO 20063843A NO 20063843 L NO20063843 L NO 20063843L
Authority
NO
Norway
Prior art keywords
gaba
agonist
polymorphic forms
new crystalline
anhydrates
Prior art date
Application number
NO20063843A
Other languages
English (en)
Norwegian (no)
Inventor
Vincent Brett Cooper
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063843(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NO20063843L publication Critical patent/NO20063843L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20063843A 2004-01-30 2006-08-29 Polymorfe formar av en GABA-A-agonist NO20063843L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist
PCT/GB2005/000288 WO2005073237A2 (en) 2004-01-30 2005-01-28 Polymorphic forms of a gabaa agonist

Publications (1)

Publication Number Publication Date
NO20063843L true NO20063843L (no) 2006-08-29

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063843A NO20063843L (no) 2004-01-30 2006-08-29 Polymorfe formar av en GABA-A-agonist

Country Status (34)

Country Link
US (2) US7262300B2 (de)
EP (2) EP1713813B1 (de)
JP (1) JP4917440B2 (de)
KR (1) KR101210361B1 (de)
CN (1) CN1914212B (de)
AR (1) AR047511A1 (de)
AT (1) ATE414088T1 (de)
AU (1) AU2005209473B2 (de)
BR (1) BRPI0506858A (de)
CA (1) CA2554536C (de)
CO (1) CO5700743A2 (de)
CY (1) CY1108647T1 (de)
DE (1) DE602005010975D1 (de)
DK (1) DK1713813T3 (de)
DO (1) DOP2005000013A (de)
EA (1) EA009413B1 (de)
EC (1) ECSP066735A (de)
ES (1) ES2314613T3 (de)
GB (2) GB0402118D0 (de)
HR (1) HRP20080614T3 (de)
IL (1) IL176863A0 (de)
MA (1) MA28364A1 (de)
MX (1) MXPA06008595A (de)
MY (1) MY139525A (de)
NO (1) NO20063843L (de)
NZ (1) NZ548191A (de)
PE (1) PE20050769A1 (de)
PL (1) PL1713813T3 (de)
PT (1) PT1713813E (de)
SI (1) SI1713813T1 (de)
TW (1) TWI345972B (de)
UA (1) UA87487C2 (de)
WO (1) WO2005073237A2 (de)
ZA (1) ZA200605307B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1848420A4 (de) 2005-01-28 2008-01-23 Merck & Co Inc Polymorphe formen eines gabaa-agonisten
CA2620374C (en) 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
ES2862673T3 (es) 2011-12-12 2021-10-07 Zilentin AG Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo
CN108024997A (zh) * 2015-07-17 2018-05-11 奥维德医疗公司 用加波沙朵治疗发育障碍的方法
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
EP3528807A4 (de) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc Verfahren zur behandlung von entwicklungsstörungen und/oder von anfällen mit flupirtin
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
EP3833351A4 (de) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. Verwendung von gaboxadol zur behandlung von tourette-syndrom, ticks und stottern
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4315934A (en) * 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
WO2001022941A1 (en) 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
HUP0400080A3 (en) 2001-05-18 2004-10-28 Lonza Ag Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate
MXPA03010596A (es) 2001-05-21 2004-03-09 Lundbeck & Co As H Preparaciones granuladas de gaboxadol.
AU2002333157A1 (en) * 2002-09-03 2004-03-29 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
EP1641456B1 (de) * 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
MXPA06015196A (es) 2004-06-29 2007-03-15 Lundbeck & Co As H Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide.
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (de) 2005-01-28 2008-01-23 Merck & Co Inc Polymorphe formen eines gabaa-agonisten
EP1863808A1 (de) 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadolformen, zusammensetzungen davon und damit in zusammenhang stehende verfahren
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol

Also Published As

Publication number Publication date
WO2005073237A3 (en) 2005-10-20
MXPA06008595A (es) 2006-08-28
SI1713813T1 (sl) 2009-02-28
EP1713813A2 (de) 2006-10-25
TWI345972B (en) 2011-08-01
UA87487C2 (ru) 2009-07-27
EA009413B1 (ru) 2007-12-28
US20050171142A1 (en) 2005-08-04
CN1914212A (zh) 2007-02-14
WO2005073237A2 (en) 2005-08-11
PL1713813T3 (pl) 2009-04-30
CN1914212B (zh) 2010-10-06
PT1713813E (pt) 2008-12-26
PE20050769A1 (es) 2005-10-04
HRP20080614T3 (en) 2009-01-31
CO5700743A2 (es) 2006-11-30
BRPI0506858A (pt) 2007-05-29
GB0402118D0 (en) 2004-03-03
GB0501847D0 (en) 2005-03-09
JP2007519697A (ja) 2007-07-19
GB2410434A (en) 2005-08-03
DOP2005000013A (es) 2005-08-15
HK1096547A1 (en) 2007-06-01
CY1108647T1 (el) 2014-04-09
US20070259912A1 (en) 2007-11-08
US8236958B2 (en) 2012-08-07
EP1713813B1 (de) 2008-11-12
NZ548191A (en) 2010-04-30
AR047511A1 (es) 2006-01-25
ECSP066735A (es) 2006-10-31
AU2005209473A1 (en) 2005-08-11
JP4917440B2 (ja) 2012-04-18
US7262300B2 (en) 2007-08-28
EA200601404A1 (ru) 2006-12-29
CA2554536C (en) 2012-09-18
ES2314613T3 (es) 2009-03-16
ZA200605307B (en) 2007-11-28
KR101210361B1 (ko) 2012-12-10
KR20070007070A (ko) 2007-01-12
ATE414088T1 (de) 2008-11-15
EP2042505A1 (de) 2009-04-01
DE602005010975D1 (de) 2008-12-24
IL176863A0 (en) 2006-10-31
CA2554536A1 (en) 2005-08-11
DK1713813T3 (da) 2009-02-16
TW200534856A (en) 2005-11-01
AU2005209473B2 (en) 2010-03-04
MA28364A1 (fr) 2006-12-01
MY139525A (en) 2009-10-30

Similar Documents

Publication Publication Date Title
UA87487C2 (ru) Полиморфные формы габоксадола, агониста gabaа, способ их получения и применение
EA200801684A1 (ru) Производные тиенопиридина как ингибиторы мек
EP2343361A4 (de) Zellkulturkit, prüfverfahren und herstellungsverfahren für das zellkulturkit
NO20084777L (no) Trinnvise sementeringsfremgangsmater som brukes ved samtidig boring og fôring
DK1698630T3 (da) Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
NO20051918D0 (no) Fremgangsmate for kontroll/overvakning av seismiske kilder
NO20081926L (no) Oppslemmingsblanding og fremgangsmåter for fremstilling av denne
BRPI0903495A2 (pt) microorganismos mutantes com capacidade de produzir putrescina e método para produção de putrescina utilizando os mesmos
DK1984744T3 (da) Fremgangsmåder og sæt til diagnostisering af væksthormonmangel
AU2008301614A8 (en) Mutant pyrrolysyl-tRNA synthetase, and method for production of protein having non-natural amino acid integrated therein by using the same
MX2009011255A (es) Proceso para preparar capecitabina.
EP2150625A4 (de) Verfahren, zusammensetzungen und kits zur erkennung und analyse von antibiotika-resistenten bakterien
WO2008066558A3 (en) Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines
DK1720848T3 (da) Derivater af alkylpiperazin- og alkylhomopiperazincarboxylater, fremgangsmåde til fremstilling heraf og anvendelse heraf som inhibitorer af enzymet FAAH
NI200800021A (es) Derivados de n - (arilalquil) - 1h - pirrolopiridin - 2 - carboxamidas, su preparación y su aplicación en terapéutica
ATE458196T1 (de) Verfahren zum apoptosenachweis
NO20083269L (no) Prosess for a anvende krystallinsk orlistatmetoder
EP1856297A4 (de) Verfahren zum nachweis klassischer schweinepest
ATE541853T1 (de) Tanaproget-derivate, metaboliten und verwendungen dafür
EA200901088A1 (ru) Способ получения 5-бензилокси-2-(4-бензилоксифенил)-3-метил-1н-индола
EA200800411A1 (ru) Новая кристаллическая форма периндоприлэрбумина
DK1753720T3 (da) Fremgangsmåde til fremstilling af perindopril og salte deraf
DK2270227T3 (da) Oligonukleotider, rækker deraf til påvisning af mikroorganismer samt apparat, fremgangsmåde og sæt til påvisning af mikroorganismer
CR9988A (es) Procedimiento para la preparación del inhibidor del ciclo celular-779 cristalino y purificado
DK2466912T3 (da) Lytteindretning med en genopladelig energikilde, som er indrettet til at blive opladet via en ITE-enhed, anvendelse af og fremgangsmåde til fremstilling deraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application